Wedbush Forecasts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at Wedbush increased their Q1 2025 EPS estimates for AnaptysBio in a research report issued to clients and investors on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous forecast of ($0.96). Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio’s Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS and FY2028 earnings at ($4.77) EPS.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%.

A number of other research firms also recently weighed in on ANAB. Truist Financial reduced their price target on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Guggenheim reduced their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Wells Fargo & Company decreased their target price on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. JPMorgan Chase & Co. reduced their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Finally, UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $16.08 on Wednesday. The stock has a 50-day simple moving average of $16.87 and a 200 day simple moving average of $26.69. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31. The company has a market cap of $489.30 million and a PE ratio of -2.64.

Institutional Trading of AnaptysBio

Several institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. grew its stake in AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after buying an additional 43,598 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of AnaptysBio by 202.8% in the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock worth $1,816,000 after acquiring an additional 36,300 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock worth $1,130,000 after acquiring an additional 22,164 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

Insider Buying and Selling at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 65,184 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the transaction, the director now owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.